DaVita Inc. (NYSE:DVA) Receives Consensus Rating of “Hold” from Analysts

DaVita Inc. (NYSE:DVA) has been assigned a consensus recommendation of “Hold” from the six research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $164.50.

Several research analysts have commented on DVA shares. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a report on Friday, April 25th. Truist Financial cut their target price on DaVita from $170.00 to $164.00 and set a “hold” rating on the stock in a report on Monday, May 19th.

DaVita Trading Up 0.6%

Shares of DVA stock opened at $136.66 on Monday. The firm has a market capitalization of $10.32 billion, a P/E ratio of 13.54, a P/E/G ratio of 0.94 and a beta of 1.11. DaVita has a twelve month low of $131.76 and a twelve month high of $179.60. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 23.18. The stock’s fifty day simple moving average is $139.84 and its 200 day simple moving average is $150.02.

DaVita (NYSE:DVA) last announced its earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping the consensus estimate of $1.75 by $0.25. The firm had revenue of $3.22 billion for the quarter, compared to the consensus estimate of $3.22 billion. DaVita had a return on equity of 176.11% and a net margin of 6.63%. The business’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the business earned $2.26 EPS. As a group, sell-side analysts predict that DaVita will post 10.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Strs Ohio acquired a new position in shares of DaVita in the 1st quarter valued at about $1,429,000. Bayforest Capital Ltd lifted its stake in shares of DaVita by 331.1% in the 1st quarter. Bayforest Capital Ltd now owns 3,259 shares of the company’s stock valued at $499,000 after purchasing an additional 2,503 shares during the period. MBB Public Markets I LLC acquired a new position in shares of DaVita in the 1st quarter valued at about $317,000. Aristeia Capital L.L.C. acquired a new position in shares of DaVita in the 1st quarter valued at about $290,000. Finally, Caxton Associates LLP acquired a new position in shares of DaVita in the 1st quarter valued at about $513,000. 90.12% of the stock is owned by institutional investors and hedge funds.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.